AbCellera Biologics Inc. Accounts Payable and Other Accrued Liabilities, Current
AbCellera Biologics Inc. (ABCL) had Accounts Payable and Other Accrued Liabilities, Current of $32.48 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Accounts Payable and Other Accrued Liabilities, Current $32.48M.
- 2026-03-31: Accounts Payable and Other Accrued Liabilities, Current $39.55M.
- 2025-12-31: Accounts Payable and Other Accrued Liabilities, Current $50.78M.
- 2025-09-30: Accounts Payable and Other Accrued Liabilities, Current $53.12M.
| Period end | Accounts Payable and Other Accrued Liabilities, Current | Accounts Payable and Other Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $32.48M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $39.55M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $50.78M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $53.12M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $50.07M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $47.84M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $55.00M 10-K · filed 2026-02-24 | |
| 2024-09-30 | $53.77M 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $43.95M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $42.89M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $49.58M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $35.71M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $52.40M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $31.81M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $52.50M 10-K · filed 2024-02-20 | $33.15M 10-K · filed 2023-02-21 |
| 2022-09-30 | $25.87M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $24.39M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $25.72M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $32.02M 10-K · filed 2023-02-21 | |
| 2021-09-30 | $24.07M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $18.28M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $13.29M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $20.20M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |